Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in leading oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors (licensed to Molecular Partners / SWX:MOLN). He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of Revolution Medicines, IDEAYA Bioscience, ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.
Mr. Schroeder is responsible for the following Nextech portfolio companies:
Revolution Medicines, Peloton Therapeutics, Kura Oncology, ImaginAb, IDEAYA Biosciences, Black Diamond Therapeutics
Portfolio companies Mr. Schroeder has been involved with previously:
Blueprint Medicines, Jounce Therapeutics